PNEUMOSTEM not checked

Medipost Co Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“A single intratracheal administration of PNEUMOSTEM® (1.0 x 10\^7 cells/kg)”In the company’s words, NCT04003857 on ClinicalTrials.gov
Tested for
Bronchopulmonary Dysplasia, BPD
Main trialPhase 2
“This is a follow-up study to investigate the long-term safety and efficacy of PNEUMOSTEM® versus placebo, for the treatment of BPD in premature infants. Subjects who participated in and completed the initial stage of the Phase II trial (NCT03392467) will be followed-up until 60 months of corrected age”In the company’s words, NCT04003857 on ClinicalTrials.gov

Other drugs for Bronchopulmonary Dysplasia

All 4 drugs for Bronchopulmonary Dysplasia

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 30 Jun 2027 Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial
Phase 2Completed 9 Jan 2024 PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow PNEUMOSTEM

Following is part of Solo: you see every change to PNEUMOSTEM the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in